Acadia reports Phase 2 RADIANT topline results for remlifanserin in Alzheimer’s disease psychosis
Acadia reported Phase 3-enabling topline results from the Phase 2 RADIANT study of remlifanserin in Alzheimer’s disease psychosis. The trial showed a modest efficacy signal at the higher dose, with the lower dose offering little benefit. Safety looked broadly comparable to placebo, with no new concerns flagged for hear